GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » ROE %

The Oncology Institute (The Oncology Institute) ROE % : -161.83% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. The Oncology Institute's annualized net income for the quarter that ended in Mar. 2024 was $-79.6 Mil. The Oncology Institute's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $49.2 Mil. Therefore, The Oncology Institute's annualized ROE % for the quarter that ended in Mar. 2024 was -161.83%.

The historical rank and industry rank for The Oncology Institute's ROE % or its related term are showing as below:

TOI' s ROE % Range Over the Past 10 Years
Min: -103.25   Med: -16.52   Max: 0.13
Current: -103.25

During the past 6 years, The Oncology Institute's highest ROE % was 0.13%. The lowest was -103.25%. And the median was -16.52%.

TOI's ROE % is ranked worse than
91.48% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.32 vs TOI: -103.25

The Oncology Institute ROE % Historical Data

The historical data trend for The Oncology Institute's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Oncology Institute ROE % Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -9.52 -40.73 -16.52 0.13 -92.20

The Oncology Institute Quarterly Data
Sep18 Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.31 -73.82 -89.00 -116.42 -161.83

Competitive Comparison of The Oncology Institute's ROE %

For the Medical Care Facilities subindustry, The Oncology Institute's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Oncology Institute's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's ROE % distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's ROE % falls into.



The Oncology Institute ROE % Calculation

The Oncology Institute's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-83.068/( (123.175+57.025)/ 2 )
=-83.068/90.1
=-92.20 %

The Oncology Institute's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-79.556/( (57.025+41.296)/ 2 )
=-79.556/49.1605
=-161.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


The Oncology Institute  (NAS:TOI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-79.556/49.1605
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-79.556 / 378.664)*(378.664 / 206.886)*(206.886 / 49.1605)
=Net Margin %*Asset Turnover*Equity Multiplier
=-21.01 %*1.8303*4.2084
=ROA %*Equity Multiplier
=-38.45 %*4.2084
=-161.83 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-79.556/49.1605
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-79.556 / -79.556) * (-79.556 / -71.888) * (-71.888 / 378.664) * (378.664 / 206.886) * (206.886 / 49.1605)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1067 * -18.98 % * 1.8303 * 4.2084
=-161.83 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


The Oncology Institute ROE % Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


The Oncology Institute (The Oncology Institute) Business Description

Traded in Other Exchanges
N/A
Address
18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Executives
Havencrest Healthcare Partners, L.p. 10 percent owner 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah officer: Chief Financial Officer, other: Principal Financial Officer C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Brad Hively director, officer: Chief Executive Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Jeremy Castle officer: Chief Operating Officer 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch director, officer: Executive Chairman C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos officer: Chief Medical Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit officer: Chief Accounting Officer, other: Principal Accounting Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal director 44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian 10 percent owner C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara director C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201